Home / Companies / Verona Pharma Plc / 24 Sep 2025
Verona Pharma Plc: meeting of 24 Sep 2025
Votes reported on Form N-PX, item by item
314 Form N-PX filers reported votes at the Verona Pharma Plc meeting of 24 Sep 2025. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
50 vote records from 45 filers. 32 of the 41 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on pay tied to a merger or sale
343 vote records from 268 filers. 48 of the 249 filers that marked the item either way voted against management. 19 filers reported this item without a management mark.
EXTRAORDINARY TRANSACTIONSIssuer
EXTRAORDINARY TRANSACTIONS: management items
Management items in this category are shown together; filers word and number them differently.
182 vote records from 80 filers. 0 of the 79 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
32 vote records from 19 filers. 1 of the 19 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Say-on-pay | 2. Merger pay |
|---|---|---|
| Vanguard | Against * | For |
| BlackRock and iShares | No report | For |
| Fidelity | No report | For |
| Dimensional | No report | Against * |
| State Street and SPDR | No report | For |
| American Century | No report | Against * |
| Franklin Templeton | No report | Against * |
| Invesco | No report | For |
| Equitable | No report | For |
| ProShares and ProFunds | No report | For |
| John Hancock and Manulife | No report | Against * |
| Morgan Stanley, Eaton Vance and Calvert | No report | For |
| J.P. Morgan | No report | For |
| Goldman Sachs | No report | For |
| PGIM and Prudential | For | For |
| Jackson National funds | No report | For |
| SEI | Against * | No report |
| T. Rowe Price | No report | For |
| First Trust | No report | For |
| Russell Investments | Against * | No report |
| Nationwide | Against * | No report |
| Brighthouse Funds | No report | Against * |
| Guggenheim and Rydex | No report | For |
| Columbia Threadneedle | No report | For |
| BNY Mellon | No report | For |
| Principal | Against * | For |
| Federated Hermes | Against * | No report |
| AllianceBernstein | No report | Against * |
| Hartford Funds | Against * | No report |
| PIMCO | No report | For |
| Allspring | No report | For |
| MassMutual | Against * | No report |
| Harbor Funds | No report | For |
| Virtus | No report | For |
| Janus Henderson | No report | For |
| Neuberger Berman | Against * | No report |
| Natixis and Loomis Sayles | No report | Against * |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Verona Pharma Plc meeting?
314 Form N-PX filers reported votes at the meeting of 24 Sep 2025. On say-on-pay, 32 of 41 voted against management (78.0%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Verona Pharma Plc on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Verona Pharma Plc
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Verona Pharma Plc with a meeting date within three days of 24 Sep 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.